Revance Therapeutics, Inc. today announced that the company will host an Investor Day on September 19, 2023, from 9:30 AM ET to 1:00 PM ET.
Interested parties can attend the live webcast for the.
- Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market.1
- Approval expands the DAXXIFY® label to include efficacy data over the 52-week ASPEN repeat dose clinical. -Today at 08:04 am- MarketScreener
- Q2 total revenue of $58.1 million, a YoY increase of 104.9%.- Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%.- Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of 47.1%.- Bolstered financial position with $100 million net proceeds from ATM program and $50 million in notes available to be.
- Q2 total revenue of $58.1 million, a YoY increase of 104.9%.
- Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%.
- Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of.
Revance Therapeutics, Inc. today announced that the company will be participating in the following investor conferences.
William Blair 43rd Annual Growth Stock Conference
Chief Executive Officer. | May 23, 2023